flow trial semaglutide all-cause mortality hazard ratio Effects of With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A Prespecified Secondary Analysis Effects of Semaglutide on Heart

Compounded GLP-1 + GIP for weight loss

Originally designed to manage type 2 diabetes (T2D), these drugs have rapidly expanded their therapeutic reach, offering significant benefits for ob

A bowel obstruction is a blockage of the intestines

Learn how injection timing affects side effects, what FDA guidelines say, and practical tips for consistent dosing to maximize your weight loss results with this once-weekly medication.

Recent Findings Results from CV outcomes trials have demonstrated the efficacy of GLP-1 RA and dual GLP-1/GIP receptor agonists to promote weight loss and improve CV outcomes across diverse populations, including reduced risk of major adverse CV events and mortality, progression of chronic kidney disease, as well as improvements in quality of life and functional status